Confirm viability
Confirm whether the combination of cytoreductive surgery and HIPEC is a viable alternative.
Specialized Unit
Peritoneal Carcinomatosis of Ovarian Origin
At Quenet-Torrent Institute, we have a specialized unit for the surgical approach to peritoneal carcinomatosis of ovarian origin. We combine cytoreductive surgery, with or without HIPEC, in a multidisciplinary environment with specialized technology.
CONTACT SPECIALISTNeed to speak with a specialist?
Complete the form and schedule your appointment to speak directly with the surgeon
-
EXTENSIVE EXPERIENCE +20,000 surgeries performed
-
LATEST TECHNOLOGY in surgical strategy
-
PERSONALIZED CARE First contact within 24/48h
Schedule your consultation with a specialist
What is ovarian peritoneal carcinomatosis?
Ovarian peritoneal carcinomatosis occurs when tumor cells spread through the peritoneum — the membrane that lines the abdominal cavity and its organs. This dissemination is a characteristic feature of advanced ovarian cancer and represents the most common pattern of spread.
It is an advanced condition, although not necessarily terminal. Advances in oncological surgery have made it possible to offer real treatment alternatives with curative intent, particularly when cytoreductive surgery is associated with HIPEC in carefully selected patients.
Ovarian cancer is one of the indications with the most documented benefit from HIPEC, especially in the context of interval surgery after neoadjuvant chemotherapy.
Why request a second opinion for ovarian carcinomatosis?
Requesting a second medical opinion is not a sign of distrust, but a responsible attitude towards a complex diagnosis.
Compare options
Compare options when initially only palliative treatment has been proposed.
Evaluate experience
Evaluate the documented experience and outcomes of the proposed center.
Updated treatment
Ensure you are receiving the most current and evidence-based treatment available.
In pathologies like ovarian carcinomatosis, time is a crucial factor, but so is making informed and well-founded decisions.
How is ovarian carcinomatosis treated?
The most effective treatment for this pathology is cytoreductive surgery, which seeks to eliminate all visible macroscopic disease, sometimes followed by HIPEC, a heated chemotherapy perfusion directly into the abdominal cavity.
Single surgical procedure
Cytoreduction and HIPEC are performed in a single surgical procedure, under general anesthesia.
Localized chemotherapy
Allows the application of high-temperature localized chemotherapy, which increases its efficacy on residual tumor cells, without the usual systemic toxicity.
Selected patients
Indicated exclusively in selected patients, after evaluation by an oncology committee.
Comprehensive assessment
At Quenet-Torrent Institute, a comprehensive assessment of each case is performed to determine treatment viability.
Our technology
Technology for ovarian carcinomatosis
The Institute has specialized equipment in a safe surgical environment adapted to highly complex procedures.
HIPEC equipment
Latest generation HIPEC perfusion equipment ensures precise control of temperature and drug concentration.
Specific instrumentation
Specific surgical instrumentation for complex peritonectomies.
Intraoperative imaging
Intraoperative imaging systems and 3D planning tools improve surgical precision.
Digital follow-up
Digital follow-up platforms for evolutionary and postoperative patient monitoring.
WHY CHOOSE US?
When it comes to ovarian carcinomatosis, every decision counts
Quenet-Torrent is not just a place where you receive medical care, it is a place where we help you face one of life's most difficult challenges with confidence and hope.
Experience in Complex Cases
We specialize in treating advanced and metastatic cancer, using innovative techniques that other teams do not offer.
Comprehensive and Multidisciplinary Approach
We form a team around you with surgeons, oncologists, radiologists, nutritionists, and psychologists, all working together for your cure.
Research and Innovation
We stay up to date with the latest scientific advances, allowing us to apply innovative treatments with better results.
State-of-the-Art Technology
We have facilities equipped with the most current medical technology, allowing us to perform high-precision procedures with less impact on the body.
Personalized and Close Care
We care about each patient as a person. We listen, support, and guide every step of the way.
What is the life expectancy in ovarian carcinomatosis?
Life expectancy in patients with peritoneal carcinomatosis varies considerably depending on multiple factors, such as the type of primary tumor, the extent of the disease, and the patient's general condition. Each case is unique and requires a personalized evaluation by a multidisciplinary team highly specialized in oncological surgery.
Our team of experts has extensive experience in managing this complex pathology, allowing us to analyze each clinical situation in detail and offer accurate information about the most current therapeutic options and specific prognosis for each patient.
Our team
Peritoneal carcinomatosis specialists
Every physician at Quenet-Torrent Institute is a recognized expert in their field, committed to the well-being of each patient.
Dr. Francois Quenet
Oncological surgeon
View doctor"As an oncological surgeon dedicated for decades to treating peritoneal carcinomatosis, I believe our main mission is to transform the approach to this stage of the disease."
Dr. Juan Jose Torrent
Oncological surgeon
View doctor"The key to success lies in three pillars: meticulous candidate selection, mastery of specialized techniques, and an expert multidisciplinary team."
Prof. Luis Gonzalez Bayon
Oncological surgeon
View doctor"Peritoneal carcinomatosis is not a single disease, but a spectrum of clinical scenarios that require individualized approaches."
Dr. Pablo Lozano Lominchar
Oncological surgeon
View doctor"Every intraoperative decision counts: maximum oncological radicality with minimum functional impact."
Dr. Clara Montagut
Medical oncologist
View doctor"Carcinomatosis surgery only makes sense within a global strategy where systemic treatments are coordinated with the intervention."
Frequently asked questions about peritoneal carcinomatosis
Answers to the most common questions about diagnosis, treatment, and prognosis.
Is peritoneal carcinomatosis always terminal?
No. In selected patients, cytoreductive surgery and sometimes its combination with HIPEC can have curative intent Outcomes depend on histology, PCI score, and completeness of cytoreduction.
Who are candidates for surgery?
Patients evaluated by a multidisciplinary oncology committee considering disease extent, general condition, and response to previous treatments Thorough preoperative assessment is essential for correct patient selection.
What risks does the intervention involve?
Complex procedure with inherent risks, but an expert team and international protocols minimize complications Experienced high-volume centres significantly reduce complication rates.
What is the estimated duration of the procedure?
Generally 6-12 hours in a single surgical procedure, depending on case complexity, with continuous adjustment based on intraoperative findings of the case.
How long is hospitalization required?
7-14 days average, depending on individual postoperative evolution, adjusted according to the patient clinical progress and response El equipo valora cada caso.
Is it possible to repeat surgery in case of recurrence?
Yes, in selected patients with localized recurrence and good general condition Our team at Quenet Torrent Institute provides individualised assessment for each case.
What is the difference between HIPEC and conventional chemotherapy?
HIPEC applies chemotherapy directly into the abdominal cavity at high temperature (41-43°C), increasing efficacy and reducing systemic toxicity Chemotherapy complements surgery to optimise overall oncological control.
What prognosis can be expected after surgery with or without HIPEC?
Varies according to tumor origin and quality of cytoreduction. Survival rates significantly higher than conventional systemic treatments Outcomes depend on histology, PCI score, and completeness of cytoreduction.
What types of tumors respond best to this approach?
Pseudomyxoma peritonei, peritoneal mesothelioma, and ovarian cancer show the best responses to combined treatment Our experienced team adapts the treatment approach to each clinical situation.
What distinguishes Quenet-Torrent Institute from other centers?
Accumulated experience in thousands of procedures, international multidisciplinary team, state-of-the-art technology, and protocols based on international scientific.
Easy Contact
Need to speak with a specialist?
Complete the form and schedule your appointment to speak directly with the surgeon.